50 related articles for article (PubMed ID: 7576445)
1. Bioavailability of buserelin and gonadorelin in suspensions.
Dolińska B; Ryszka F; Szulc B
Boll Chim Farm; 1995 Sep; 134(8):459-60. PubMed ID: 7576445
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Bioavailability of the GnRH Analogs in the Form of Solution and Zn
Suszka-Świtek A; Ryszka F; Dolińska B; Dec R; Danch A; Filipczyk Ł; Wiaderkiewicz R
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):251-259. PubMed ID: 27180066
[TBL] [Abstract][Full Text] [Related]
3. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats.
Matsubara K; Abe K; Irie T; Uekama K
J Pharm Sci; 1995 Nov; 84(11):1295-300. PubMed ID: 8587046
[TBL] [Abstract][Full Text] [Related]
4. Preparation and properties of buserelin suspensions.
Ryszka F; Dolińska B; Szulc B; Zientarska G
Boll Chim Farm; 1994 Mar; 133(3):156-9. PubMed ID: 8011275
[TBL] [Abstract][Full Text] [Related]
5. Disposition of 3H-labelled buserelin continuously infused into rats.
Heinrich N; Albrecht E; Sandow J; Kertscher U; Lorenz D; Oehlke J; Berger H
Eur J Drug Metab Pharmacokinet; 1996; 21(4):345-50. PubMed ID: 9074900
[TBL] [Abstract][Full Text] [Related]
6. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
Schlegel P
BJU Int; 2009 Mar; 103 Suppl 2():7-13. PubMed ID: 19228147
[No Abstract] [Full Text] [Related]
7. Sustained release of buserelin acetate, a luteinizing hormone-releasing hormone agonist, from an injectable oily preparation utilizing ethylated beta-cyclodextrin.
Uekama K; Arima H; Irie T; Matsubara K; Kuriki T
J Pharm Pharmacol; 1989 Dec; 41(12):874-6. PubMed ID: 2576455
[TBL] [Abstract][Full Text] [Related]
8. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo.
Luessen HL; de Leeuw BJ; Langemeÿer MW; de Boer AB; Verhoef JC; Junginger HE
Pharm Res; 1996 Nov; 13(11):1668-72. PubMed ID: 8956332
[TBL] [Abstract][Full Text] [Related]
9. Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.
Berger H; Sandow J; Heinrich N; Albrecht E; Kertscher U; Oehlke J
Drug Metab Dispos; 1993; 21(5):818-22. PubMed ID: 7902242
[TBL] [Abstract][Full Text] [Related]
10. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
11. Use of gonadotropic releasing hormone for ovulating the rabbit model.
Foote RH; Simkin ME
Lab Anim Sci; 1993 Aug; 43(4):383-5. PubMed ID: 8231104
[No Abstract] [Full Text] [Related]
12. Effects of short-course buserelin therapy on adenomyosis. A report of two cases.
Huang FJ; Kung FT; Chang SY; Hsu TY
J Reprod Med; 1999 Aug; 44(8):741-4. PubMed ID: 10483548
[TBL] [Abstract][Full Text] [Related]
13. Estimation of human effective absorbed dose of 67Ga-cDTPA-gonadorelin based on biodistribution rat data.
Shanehsazzadeh S; Lahooti A; Sadeghi HR; Jalilian AR
Nucl Med Commun; 2011 Jan; 32(1):37-43. PubMed ID: 21068688
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity.
Mezô I; Seprôdi J; Vincze B; Pályi I; Kéri G; Vadász Z; Tóth G; Kovács M; Koppán M; Horváth JE; Kálnay A; Teplán I
Biomed Pept Proteins Nucleic Acids; 1996; 2(2):33-40. PubMed ID: 9346824
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents.
Marchetti JM; Shuhama IK; Bentley MV; Lara EH
Boll Chim Farm; 1999 Oct; 138(9):461-4. PubMed ID: 10682404
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the buserelin stimulation test in diagnosing gonadotropin deficiency in males with delayed puberty.
Wilson DA; Hofman PL; Miles HL; Unwin KE; McGrail CE; Cutfield WS
J Pediatr; 2006 Jan; 148(1):89-94. PubMed ID: 16423605
[TBL] [Abstract][Full Text] [Related]
17. Dosage of buserelin.
Yu N
J Reprod Med; 2000 Nov; 45(11):964-5. PubMed ID: 11127117
[No Abstract] [Full Text] [Related]
18. Optimizing assisted reproduction: impact of low-dose gonadotropin-releasing hormone agonist on in vitro fertilization outcome.
Lenton E; Mohamed K
Fertil Steril; 2005 Dec; 84(6):1783-5. PubMed ID: 16359992
[TBL] [Abstract][Full Text] [Related]
19. GnRH antagonists in poor responders.
Kolibianakis E; Albano C; Zikopoulos K; Kahn JA; Van Steirteghem A; Devroey P
Acta Obstet Gynecol Scand; 2004 Dec; 83(12):1216-7. PubMed ID: 15548159
[No Abstract] [Full Text] [Related]
20. Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line.
Shibata S; Sato H; Ota H; Karube A; Takahashi O; Tanaka T
Gynecol Oncol; 1997 Aug; 66(2):217-21. PubMed ID: 9264565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
